Biologics

MiMedx releases AmnioFix Injectable

MiMedx Group Inc. announced the launch of its newest tissue product, AmnioFix Injectable, at the American Academy of Orthopaedic Surgeons 2012 Annual Meeting in San Francisco.

 According to a company press release, AmnioFix Injectable is an allograft composed of micronized amniotic tissue, which is processed to optimize surgical performance and ease of use. The company’s proprietary Purion process retains the amniotic growth factors and cytokines inherent in and unique to placental tissue, resulting in an injectable tissue that offers a natural ability to reduce inflammation at the injection site and enhance soft tissue healing. AmnioFix has a 5-year shelf-life.
Tags

Josh Sandberg

Josh Sandberg is the President of Ortho Sales Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close
Themed By teapots